Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
20 results
D1.244 - Clinical heterogeneity of pediatric atopic dermatitis: latent class analysis
D1.241 - Clinical and Immunological Phenotypes of Alopecia Areata in Children with Atopic Dermatitis
D1.236 - The role of tissue resident memory cells in immunodermatological disorders: A Systematic Review
D1.237 - Mental Health and Neurodevelopmental Comorbidities in Pediatric Atopic Dermatitis: A Retrospective Study and Literature-Based Perspective
D1.245 - The role of advanced glycation end products as facilitating factors in the pathogenesis of atopic dermatitis in pediatric patients
D1.246 - Characterization of Unmet Need for Targeted Precision Medication in Atopic Dermatitis Due to Inadequate Response or Adverse Reactions to Dupilumab
D2.480 - Features of the molecular sensitization profile in children with autism spectrum disorder
D2.485 - Comprehensive Understanding of the Characteristics of Pediatric Pollen Allergy Patients
D2.486 - Levels of house dust mite in dust settlements are associated with risk for allergic rhinitis in children
D2.479 - The bullous pemphigoid in a baby
D2.481 - Severe obstructive syndrome in children with bronchopulmonary malformations
D2.488 - Functional confirmation of exercise-induced bronchoconstriction in children: A three-year retrospective study
D3.419 - Efficacy, safety, and remission outcomes of omalizumab in elderly patients with severe allergic asthma: a subgroup analysis by age of onset
D3.420 - Real-world epidemiologic characteristics of patients treated with dupilumab for type 2 inflammatory indications: a single-center retrospective cohort study
D3.422 - Dupilumab in children with multimorbid atopic phenotype: therapy efficacy, safety and biomarker changes
D3.424 - Retrospective Analysis of Self-Administration of Biologic Treatments for Severe Asthma and Chronic Urticaria
D3.426 - Predicting response to omalizumab in patients with chronic spontaneous urticaria: The first results of the global multicenter UCARE SCOPUS project
D3.427 - Challenging the paradigm: Use of omalizumab in refractory angioedema in a 2-year-old child
D3.428 - Substratification of Biologic Treatment Using Dupilumab in Eosinophilic COPD
D3.417 - Dupilumab in pediatric patients with severe atopic dermatitis
Download the app
The congress at your fingertips
Available on
Download